(Q34572002)

3 August 2017

1 reference

title

Vaccines for melanoma: translating basic immunology into new therapies (English)

1 reference

3 August 2017

0 references

J D Wolchok

1

1 reference

PubMed ID

11905765

3 August 2017

P O Livingston

series ordinal

2

1 reference

3 August 2017

1 April 2001

1 reference

Lancet Oncology Commission

3 August 2017

1 reference

3 August 2017

2

1 reference

3 August 2017

205-211

1 reference

3 August 2017

4

1 reference

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

3 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900290-4

7 January 2021

A critique of the evidence for active host defence against cancer, based on personal studies of 27 murine tumours of spontaneous origin

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900290-4

7 January 2021

IgM anti-ganglioside antibodies induced by melanoma cell vaccine correlate with survival of melanoma patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900290-4

7 January 2021

Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900290-4

7 January 2021

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900290-4

7 January 2021

Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900290-4

7 January 2021

A case report: immune responses and clinical course of the first human use of granulocyte/macrophage-colony-stimulating-factor-transduced autologous melanoma cells for immunotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900290-4

7 January 2021

A phase I study of vaccination with autologous, irradiated melanoma cells engineered to secrete human granulocyte-macrophage colony stimulating factor.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900290-4

7 January 2021

Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900290-4

7 January 2021

Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900290-4

7 January 2021

Induction of antibodies against GD3 ganglioside in melanoma patients by vaccination with GD3-lactone-KLH conjugate plus immunological adjuvant QS-21.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900290-4

7 January 2021

Disialoganglioside GD2 anti-idiotypic monoclonal antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900290-4

7 January 2021

Clinical and immune responses in advanced melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900290-4

7 January 2021

Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900290-4

7 January 2021

Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900290-4

7 January 2021

Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: implications for tumor vaccines with melanoma-associated antigens

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900290-4

7 January 2021

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900290-4

7 January 2021

Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900290-4

7 January 2021

Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900290-4

7 January 2021

CpG DNA induces stronger immune responses with less toxicity than other adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900290-4

7 January 2021

Novel responses of human skin to intradermal recombinant granulocyte/macrophage-colony-stimulating factor: Langerhans cell recruitment, keratinocyte growth, and enhanced wound healing

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900290-4

7 January 2021

Heat shock protein-peptide complexes for use in vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900290-4

7 January 2021

Generation of tumor-specific cytotoxic T lymphocytes and memory T cells by immunization with tumor-derived heat shock protein gp96.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900290-4

7 January 2021

Heat shock protein-peptide complexes in cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900290-4

7 January 2021

Purification of heat shock protein-peptide complexes for use in vaccination against cancers and intracellular pathogens

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900290-4

7 January 2021

Heat shock protein-based cancer vaccines and related thoughts on immunogenicity of human tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900290-4

7 January 2021

Receptor-mediated uptake of antigen/heat shock protein complexes results in major histocompatibility complex class I antigen presentation via two distinct processing pathways

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900290-4

7 January 2021

Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T cells after gene gun immunization.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900290-4

7 January 2021

Antigen presentation by dendritic cells after immunization with DNA encoding a major histocompatibility complex class II-restricted viral epitope

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900290-4

7 January 2021

DNA vaccination: transfection and activation of dendritic cells as key events for immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900290-4

7 January 2021

CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900290-4

7 January 2021

Immunostimulatory DNA sequences necessary for effective intradermal gene immunization

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900290-4

7 January 2021

Coupling and uncoupling of tumor immunity and autoimmunity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900290-4

7 January 2021

Immunization with DNA coding for gp100 results in CD4 T-cell independent antitumor immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900290-4

7 January 2021

Tumor immunity and autoimmunity induced by immunization with homologous DNA

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900290-4

7 January 2021

Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900290-4

7 January 2021

Vaccination of seronegative volunteers with a human immunodeficiency virus type 1 env/rev DNA vaccine induces antigen-specific proliferation and lymphocyte production of beta-chemokines

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900290-4

7 January 2021

DNA vaccination with HIV-1 expressing constructs elicits immune responses in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900290-4

7 January 2021

Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900290-4

7 January 2021

Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900290-4

7 January 2021

10.1016/S1470-2045(00)00290-4

Identifiers

DOI

1 reference

3 August 2017

1 reference

PubMed ID

11905765